Background: Current guidelines advocate for antiretroviral therapy (ART) simplification in patients on complicated regimens. Simplifying ART improves patient adherence and quality of life, but changes in drug interactions (DIs) are uncertain. Objective: This study assessed changes in DIs following ART simplification in patients with HIV. Methods: This was an observational, retrospective cohort study of patients attending an urban HIV clinic. Patients were included if they had ART simplification (a decreased number of daily tablets) and ≥1 concomitant medication (CM). Total DI scores were generated for each patient pre-ART simplification and post-ART simplification using an online DI database. Each ART-CM pair labeled as "do not co-administer" was given a score of 2, "potential interaction" a score of 1, or "no interaction" a score of 0. Differences in total DI scores following simplification were analyzed with a Wilcoxon Signed-Rank test. Predictors of DI score reductions were examined with linear regression. Results: A total of 99 patients were included. Their median age was 54 years, and 79% were male. The median durations of HIV infection and ART were 16 and 10 years, respectively. Patients were receiving an average of 4.5 CMs. Median interaction scores presimplification and postsimplification were 3 (interquartile range [IQR], 1-6) and 1 (IQR, 0-2) respectively (P < 0.001). Predictors of score reductions were the patient's number of CMs, discontinuing a protease inhibitor, and switching to a dolutegravir-based regimen. Conclusion and Relevance: ART simplification decreased the incidence of DIs in this analysis of patients with advanced age who had ART experience and polypharmacy.
Background
Simplified HIV treatment regimens have long been associated with better adherence and treatment outcomes among patients living with HIV (PLWH). [1] [2] [3] [4] [5] [6] [7] Fortunately, several combination tablets, including single-tablet regimens, with effective, safe, and well-tolerated agents have emerged. These regimens are now routinely used in treatment-naïve patients, and several have a role in helping simplify therapy for select patients with treatment experience. 8 As a result, antiretroviral therapy (ART) simplification has become increasingly common and is among the most common reasons for ART modification. [9] [10] [11] Current treatment guidelines advocate for ART simplification when possible in virologically suppressed patients receiving complicated regimens. 12 Prior to simplification, a patient's full HIV treatment history must be evaluated. This includes past virological responses, failures, and resistance as well as any instances of poor tolerability or ARTassociated toxicities. These factors will inform the feasibility of regimen simplification and influence the simplification options for patients that will maintain treatment success.
Drug-drug interaction (DDIs) assessments must also occur prior to ART simplification. More than 50% of the HIV population is older than 50 years, and many are receiving 5 or 1 Jefferson College of Pharmacy, Thomas Jefferson University, Philadelphia, PA, USA more medications for common chronic conditions. 13, 14 In one recent study, PLWH older than 50 years were receiving an average of at least 11 medications in addition to the ART, with one-third of the study sample on at least 16 concomitant agents. 14 Cardiovascular disease, hepatic and renal disease, osteoporosis, insulin resistance, metabolic disorders, and cancers occur commonly in PLWH. 15 DDIs between medications needed to treat or prevent these comorbid conditions can often interact with ART. Switching ART, in many circumstances, can reduce the number of drug interactions (DIs). However, switching can also lead to new interactions requiring intervention to avoid toxicity or prevent ineffective treatment.
Multiple studies have confirmed that simplifying HIV treatment can improve patient adherence and quality of life. [4] [5] [6] [7] Several studies have also confirmed that clinically significant DDIs are common in PLWH, but none have assessed changes in the incidence and severity of DDIs in the setting of ART simplification. [16] [17] [18] The primary objective of this study was to assess changes in the incidence and severity of DDIs before and after ART simplification in treatment-experienced patients.
Methods
This was an observational, retrospective cohort study involving a sample of patients undergoing active medication treatment for HIV infection at a single urban center in Philadelphia, Pennsylvania. Consecutive adult patients receiving at least 1 concomitant medication (CM) and undergoing ART simplification between June 2014 and May 2018 were evaluated. ART simplification was defined as changes to an HIV regimen made to reduce the frequency of doses and/or the total number of pills per day.
Demographic information, including age, sex, race, duration of infection, years on ART, number of previous regimens, CD4 count, and HIV RNA at the time of simplification were collected for all patients. Details regarding patient medications at the time of ART simplification were also collected, including drug name, strength, dose, route, frequency, and duration. This research protocol was approved by the Institutional Review Board at Thomas Jefferson University.
DDI Scoring System
To assess the combined incidence and severity of DDIs with CMs at the time of ART simplification, a DDI incidence and severity score was developed and validated. The score is based on results obtained when entering medications into the University of Liverpool's HIV Drug Interaction Checker (ULHDIC) database (https://www.hivdruginteractions.org/checker). Each ART-CM pair was given one of the following scores: "do not co-administer" was assigned a score of 2, "potentially significant interaction" a score of 1, and "no interaction" a score of 0. For those interactions that had "no clear data," or for those medications that were not listed in the drug database, the Department of Health and Human Services HIV treatment guidelines and Food and Drug Administration (FDA) product labeling were used for scoring.
To validate the scoring system, a separate analysis was completed. The medication profiles of a random, representative sample of the study population were selected (n = 20). DI scores using the aforementioned ULHDIC were compared with scores determined manually using the Department of Health and Human Services HIV treatment guidelines and FDA product labeling. Scores using each method were then compared using a Wilcoxon Signed Rank test. No differences in DI scores between methods were observed.
Data Analysis and Statistical Methods
Patient characteristics at the time of ART simplification were analyzed with descriptive statistics. Continuous variables were examined for normality and are presented as means with SDs or medians with interquartile ranges (IQRs) as appropriate. Categorical variables are presented as counts with percentages.
The total DDI scores for each patient presimplification and postsimplification were calculated. On the date that ART simplification occurred, a patient's CMs were identified and evaluated for DDIs with both the presimplification and postsimplification ART regimens. Presimplification and postsimplification scores were then determined and analyzed for statistical differences using a Wilcoxon Signed Rank test. An α level of 0.05 was used to determine statistical significance.
Predictors for achieving DI score reductions were examined using a multivariable linear regression model. Because the values representing the differences in DI scores following ART simplification showed a negatively skewed distribution, models were built using reflection and log-transformation. Initial models included all a priori determined variables, and all variables were examined for multicollinearity. Models were fit using a backward selection procedure. Candidate predictors were eliminated individually by comparing the log-likelihood ratio test for each model step and using the 5% significance level. All statistical analyses were performed using SPSS software, version 8.1 (Version 25.0, Armonk, NY: IBM Corp).
A sample size of 90 patients was required to provide 80% power to detect a significant difference in DI score presimplification and postsimplification, using a Wilcoxon Signed-Rank test with an α level set at 0.05 and an effect size of 0.3 (G*Power, Version 3.1, Universität Düsseldorf).
Results

Patient Characteristics
A total of 99 patients met criteria for study inclusion (Table 1 ). Their median age was 54 years, and most were male. The majority were also black or African American with longstanding HIV-1 infection. Most patients were virally suppressed at the time of simplification, with a median CD4 + cell count of 516 cells/mm 3 .
Considerable HIV treatment experience was common among participants. The median duration of ART was 10 years, and more than half had received at least 2 prior ART regimens. Patients were taking a median of 3 ART pills daily, and more than one-third were receiving twice-daily regimens. Nearly 17% were receiving antiretrovirals from 3 or more drug classes. Aside from their ART, patients were receiving a median of 5 additional medications.
Switch Characteristics
After ART simplification, the median number of ART pills taken daily was reduced by 2. Switches to a single-tablet regimen from a non-single-tablet regimen were common, encompassing 57% of regimen changes. No patients were receiving twice-daily regimens postsimplification, but those receiving agents from 3 or more drug classes increased to 25%.
Data regarding intraclass and interclass switches are available in Table 2 . One of the most common ART changes was a switch to an integrase strand transfer inhibitor (INSTI)-based regimen from a regimen without an INSTI, encompassing 67% of switches. Of these, 47% of participants started dolutegravir (DTG) and 52% started elvitegravir (ELV). Discontinuing a protease inhibitor (PI) occurred frequently as well; 48 of the 75 patients taking a PI as a part of their previous regimen did not continue them with their postsimplification regimen. Discontinuing a nonnucleoside reverse transcriptase inhibitor (NNRTI) was also common; 13 of 16 patients on an NNRTI presimplification did not continue these agents postsimplification. Finally, in terms of the nucleos(t)ide reverse transcriptase inhibitors (NRTIs), the most common regimen alteration was a change to tenofovir alafenamide (TAF) plus emtricitabine (FTC); 60% of the participants on NRTIs postsimplification had a regimen containing TAF/FTC.
DDIs Presimplification and Postsimplification
There was a statistically significant difference in DI scores presimplification to postsimplification (P < 0.001). Median interaction scores presimplification and postsimplification were 3 (IQR, 1-6) and 1 (IQR, 0-2), respectively. Whereas most patients (55%) experienced a reduction in their interaction score postsimplification, the scores for many patients (30%) did not change, and only a small percentage (15%) experienced a score increase.
The types of CMs that interacted most frequently with ART differed presimplification and postsimplification. The PIs were the most commonly implicated antiretrovirals presimplification, interacting most often with medications metabolized by the cytochrome P450 (CYP450) system. These medications included antidepressants, anxiolytics, antihypertensives (ie, amlodipine), statins, phosphodiesterase-5 inhibitors, and inhaled corticosteroids. Interactions with these medications were infrequent postsimplification because many PIs were removed from ART regimens. However, the interactions often persisted if the patient switched from a PI to an ELV/cobicistat-containing combination. Other common interactions postsimplification occurred between INSTIs and products containing multivalent cations.
The incidence of severe interactions (contraindications) was similar presimplification and postsimplification. There were 21 severe interactions out of 348 total interactions (6.03%) presimplification, and 16 out of 238 (6.72%) postsimplification. All contraindications occurred as a result of CYP450 3A4 substrates used in combination with strong 3A4 inhibitors such as PIs or cobicistat presimplification and postsimplification. The frequency of each interaction is shown in Table 3 .
Predictors for Achieving Score Reductions
The number of CMs a patient was receiving was important in terms of predicting DI score reductions following ART simplification. According to the linear regression model, for each CM a patient was receiving, regimen simplification led to a 1-point reduction in a patient's DI score (Table 4 ). In terms of ART changes, predictors for achieving score reductions following regimen simplification identified by the regression model were discontinuing a PI, which corresponded to a 1.47-point reduction and switching to an INSTI-based regimen that included DTG as opposed to ELV, which corresponded to a 1.27-point reduction ( Table  4 ). Switching or discontinuing NNRTIs and NRTIs was not associated with DI score reductions in this study.
Discontinuing a Protease Inhibitor. Of the 48 patients who discontinued PIs, 37 (77%) experienced a DDI score reduction, with a median decrease of −2 points (IQR, −3.75 to −1). The majority (42/48) switched their PI to an INSTI, which was also associated with a median score change of −2 points (IQR, −4 to −1). The most common switches to an INSTI were from darunavir/ritonavir or atazanavir/ritonavir. These switches led to similar DI score reductions.
Switching to an Integrase Inhibitor. A total of 66 participants were switched to INSTI-containing regimens, of whom 52 experienced a median DI score change of −1 point (IQR, −2 to 0). Switches to DTG-based regimens accounted for a median score change of −2 points (IQR, −6 to −1), whereas switches to ELV-based regimens resulted in no score reductions (median = 0; IQR, −1 to +1).
Switching or Discontinuing NNRTIs and NRTIs. In the 13 patients who discontinued NNRTIs, 7 experienced a reduction in their interaction score, with a median change of −0.5 points (IQR, −3.5 to 0.75). The majority of these patients (92%) discontinued NNRTIs and added an INSTI to their postsimplification regimen. In terms of the NRTIs, of the 58 patients who started TAF/FTC postsimplification, the median interaction score change was −1 point (IQR, −2 to 0). Of the 58, 30 (52%) experienced an overall DDI score reduction. For those patients who experienced a score reduction, the median change was −2 points (IQR, −3 to −1). However, within the regression analysis, switching to TAF/FTC was highly correlated with switching to INSTI-based regimens. This likely explains the majority of DDI score reductions observed in patients switching to TAF/FTC.
Discussion
Simplifying ART reduced the incidence of DDIs for participants in this study. The most substantial reductions occurred for patients receiving multiple CMs. PLWH are more likely to experience polypharmacy compared with HIV-negative persons, with the highest rates occurring in those older than 50 years. 19, 20 Polypharmacy is associated with more DDIs in PLWH and has been linked to poor health outcomes in this population. [21] [22] [23] In our sample, most patients were older than 50 years and receiving 5 CMs. Simplifying ART reduced DDIs for many of these patients, with greater reductions occurring as the number of CMs increased. As a result, in addition to reducing pill burden and improving health outcomes, ART simplification in PLWH and polypharmacy can considerably reduce exposures to DDIs.
Importantly, DDI reductions in this study were only associated with certain antiretroviral changes. Presimplification, patients were more likely to be taking ART regimens containing PIs. These agents are CYP450 3A4 substrates, strong 3A4 inhibitors, and can often influence other common pathways for medication absorption, metabolism, and elimination. Because of their 3A4 inhibition, specifically, their use often results in dosage restrictions, adjustments, and close monitoring of CMs and, at times, contraindications. Common examples include antidepressants, statins, and inhaled corticosteroids, which many study participants were receiving. As a result, discontinuing a PI during ART simplification in this study was among the strongest predictors for reducing DDIs. On the other hand, maintaining a PI as a component of the post-ART regimen was a common reason why the incidence of severe interactions did not change with ART simplification.
The INSTIs were the most common components of ART regimens postsimplification in this study. Individual members of this drug class differ in their DDI potential. DTG and bictegravir are metabolized primarily through glucuronidation. They do not inhibit or induce the metabolism of other medications but can inhibit the elimination of certain medications removed by active secretion in the proximal tubule (eg, metformin). Like all INSTIs, they are also subject to chelation interactions with polyvalent cations present in multivitamins and antacids. In contrast, ELV is primarily metabolized by CYP450 3A4 and is coformulated with cobicistat, a potent CYP450 3A4 inhibitor and pharmacoenhancer. The presence of cobicistat leads to DDIs through the CYP450 3A4 pathway that are similar to those encountered with PIs, resulting in similar dosage restrictions, adjustments, and contraindications. The differences between DTG and ELV in terms of their DDI potential are reflected in the results of this study.
Notably, switching to a DTG-based regimen was a significant predictor of DDI score reductions, whereas switching to an ELV-based regimen was not. The present study is not without limitations. First, it involved a small number of patients at a single center in an urban setting that may not reflect the HIV population as a whole. However, the study sample is consistent with the ART-experienced and aging HIV population who have multiple comorbid conditions and are receiving several CMs. Second, not all HIV medications and ART simplification strategies could be thoroughly evaluated in this study. For example, only a small number of patients were receiving NNRTI-containing regimens presimplification. Because NNRTIs are CYP450 substrates and some are CYP450 inducers, a reduction in DDIs postsimplification may have been expected. However, discontinuing an NNRTI was not identified as a predictor for score change in this study. Third, because this study was a review of electronic medical records, the results are reliant on the accuracy and completeness of each patient's chart. In particular, it is possible that medication profiles did not consistently include any nonprescription medications or over-the-counter supplements patients may have been using. Finally, although the DDI scoring system can provide information on the incidence and severity of DDIs, scores do not reflect the clinical significance of each interaction encountered. For example, certain interactions may require agents to be dose adjusted or more closely monitored. Changes in these requirements can occur during ART switches, but this could not be quantified using the scoring system and, therefore, was not assessed in this study. Furthermore, DIs can vary in terms of how they are interpreted and managed by providers, which also could not be determined with this analysis.
Conclusion and Relevance
For treatment-experienced PLWH, we found that simplifying ART regimens leads to a reduction in the frequency, but not always the severity of DDIs with CMs. The reductions occurred more commonly when discontinuing a PI, when switching to a DTG-based regimen, and among patients with more CMs. Because simplification also resulted in a lesser pill burden, patient convenience and adherence may be improved. This trial supports the current guideline's recommendations, and its findings may be used to inform ART simplification decisions.
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